« Back
Home /
Wortmannin

Wortmannin

Item no.	HY-10197-5mg
Manufacturer	MedChem Express
CASRN	19545-26-7
Amount	5 mg
Quantity options	100 mg 10mM/1mL 10 mg 1 mg 25 mg 50 mg 5 mg
Category	Oncology Food Safety Histamines Neuroscience Molecular Targets for Neuroscience Cardiovascular Research Thrombosis & Hemostasis Heart Failure Myocardial Infarction Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Colorectal Cancer
Type	Inhibitors
Specific against	other
Purity	99.86
Formula	C23H24O8
Citations	[1]Yano H, et al. Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells. J Biol Chem. 1993 Dec 5;268(34):25846-56.<br/>[2]Moon EK, et al. Autophagy inhibitors as a potential antiamoebic treatment for Acanthamoeba keratitis. Antimicrob Agents Chemother. 2015 Jul;59(7):4020-5.<br/>[3]Liu Y, et al. Polo-like kinases inhibited by wortmannin. Labeling site and downstream effects. J Biol Chem. 2007 Jan 26;282(4):2505-11.<br/>[4]Wu Q, et al. Wortmannin inhibits K562 leukemic cells by regulating PI3k/Akt channel in vitro. J Huazhong Univ Sci Technolog Med Sci. 2009 Aug;29(4):451-6.<br/>[5]Lemke LE, et al. Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3-kinase. Cancer Chemother Pharmacol. 1999;44(6):491-7.<br/>[6]Liu Y, et al. Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalianpolo-like kinase. Chem Biol. 2005 Jan;12(1):99-107.<br/>[7]Pobbati AV, et al. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy. Theranostics. 2020 Feb 18;10(8):3622-3635.
Smiles	O=C1C([C@@](CC2)([H])[C@@]3(C)C2=O)=C([C@H](OC(C)=O)C3)[C@]4(C)C5=C1OC=C5C(O[C@@H]4COC)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	SL-2052; KY-12420
Available
Product Description	Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC50 of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and Plk3 with IC50s of 5.8 and 48 nM, respectively[1][2][3].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	428.43
Clinical Information	No Development Reported
Manufacturers Research Area	Cancer
Solubility	DMSO : ≥ 50 mg/mL
Target	Antibiotic; Autophagy; Organoid; PI3K; Polo-like Kinase (PLK)
Manufacturers Target	Antibiotic; Autophagy; Organoid; PI3K; Polo-like Kinase (PLK)
Isoform	ATM; ATR; PI3K; PLK3
Manufacturers Pathway	Anti-infection; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-10197-5mg-safety-datasheet.pdf